News
SynaptixBio receives incurable disease research boost
Oxford-based SynaptixBio – a company focused on treating the genetic central nervous system disease TUBB4A-related leukodystrophy – has gained £11.05m in its latest financing project.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Oxford-based SynaptixBio – a company focused on treating the genetic central nervous system disease TUBB4A-related leukodystrophy – has gained £11.05m in its latest financing project.